Just weeks af­ter bag­ging $52 mil­lion from ven­ture cap­i­tal­ists in a crossover round, Cam­bridge, MA dar­ling Ma­gen­ta Ther­a­peu­tics has de­clared in­ten­tions to list on the Nas­daq in an IPO an­gling at $100 mil­lion.

Ac­cord­ing to a state­ment filed with the SEC, the cash will be used to push for­ward Ma­gen­ta’s most ad­vanced clin­i­cal pro­gram: a cell ther­a­py called MG­TA- 456. The drug, cur­rent­ly in Phase II tri­als, is be­ing test­ed in pa­tients with in­her­it­ed meta­bol­ic dis­or­ders. Ma­gen­ta says new IPO mon­ey would push the treat­ment through a piv­otal tri­al, pay for some com­mer­cial­iza­tion ac­tiv­i­ties, and al­so fund re­search in­to ad­di­tion­al in­di­ca­tions for the ther­a­py, such as sick­le cell dis­ease and blood can­cers.

Be­yond that, Ma­gen­ta might use the new funds to back MG­TA-145, a nov­el stem cell mo­bi­liza­tion prod­uct can­di­date.

Ma­gen­ta, with its lofty goals of im­prov­ing stem cell trans­plan­ta­tion, has been mak­ing a splash in the big Cam­bridge/Boston hub, pre­vi­ous­ly gath­er­ing some­thing like $150 mil­lion in ven­ture cash from some mar­quee in­vestors that in­clude GV – the ven­ture group for­mer­ly known as Google Ven­tures – and in-li­cens­ing a mid-stage drug that No­var­tis thinks high­ly of for en­hanc­ing cord blood stem cells as a treat­ment.

Third Rock has the biggest chunk of eq­ui­ty, with 29% of the stock, while At­las has 17% and GV weighs in at 12%.

Ja­son Gard­ner

CEO Ja­son Gard­ner, a GSK vet who joined the ex­o­dus in­to the boom­ing biotech field, has a 3.7% stake in the com­pa­ny.

In March, Ma­gen­ta teamed up with Ger­man biotech Hei­del­berg Phar­ma on a bone mar­row R&D pact that in­clud­ed $334 mil­lion in po­ten­tial mile­stone pay­ments. And in Feb­ru­ary, Ma­gen­ta re­cruit­ed Big Phar­ma R&D ex­ec John Davis, for­mer­ly of Pfiz­er, to serve as the com­pa­ny’s new chief med­ical of­fi­cer.

Ma­gen­ta plans to list on the Nas­daq un­der the stock sym­bol $MG­TA.

The FDA’s Oncology Center of Excellence has been a bright spot within the agency in terms of speeding new treatments to patients. That flexibility was on full display this morning as FDA released new draft guidance spelling out exactly how oncology drug developers can fulfill both the accelerated and full approval’s requirements with just a single randomized controlled trial.

While Congress recently passed legislation that will allow FDA to require confirmatory trials to be recruiting and ongoing prior to granting an accelerated approval, the agency is now making clear that the initial trial used to win the AA, if designed appropriately, can also serve as the trial for converting the accelerated approval into a full approval.

US regulators cleared an ultra-rare drug from Pharming Group, by way of Novartis, on Friday afternoon.

The Dutch biotech said the FDA greenlit leniolisib for an immunodeficiency disease known as activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome, or APDS. People 12 years and older can receive the oral drug, to be marketed as Joenja, beginning early next month, Pharming said, five days ahead of the decision deadline set by the FDA as part of a priority review.

A California judge will allow a plaintiff in a state court case to introduce expert testimony connecting a potential carcinogen in former blockbuster medicine Zantac to cancer.

The order was handed down on Thursday from state judge Evelio Grillo, who is now allowing both parties to introduce expert testimony in an upcoming trial after what’s known as a Sargon hearing, where a judge determines the admissibility of expert witnesses and expert opinions.